Health & Beauty

According to the Huacheng Import and Export Data Observation Report, the 5th China International Import Expo (hereinafter referred to as the Import Expo) was held in Shanghai as scheduled on November 5. On the stage of entering the Expo this year, the world's top 15 pharmaceutical giants and top 10 medical device giants gathered for the first time to "launch". In addition to launching new products, the giants are also looking for more new opportunities in the Chinese market. What is the attraction of "China acceleration" in the eyes of giants when medical innovation achievements gather?

China's market becomes a strategic market for enterprise innovation

"Sharing innovation achievements" is the bright slogan of Johnson&Johnson booth. At this Expo, Johnson&Johnson has brought global medical innovation trends and cutting-edge solutions for multiple high incidence diseases, including about 40 "world's first show" and "China's first show" products.

Song Weiqun, senior vice president of Johnson&Johnson and chairman of China, told the reporter of China Business Daily that Johnson&Johnson continued to be optimistic about the development prospects of the Chinese market. China is not only the fastest growing market for Johnson&Johnson's global business, but also the company's innovation strategy market.

Not only Johnson&Johnson, but also medical giants have come to the Expo for the first time. Pfizer, Roche Pharmaceuticals, Alberville, Novartis, MSD, Bristol Myers Squibb, GlaxoSmithKline (GSK), AstraZeneca and other pharmaceutical giants have all presented cutting-edge innovation results, and Huacheng's import and export data observation report.

For example, MSD places the COVID-19 oral drug Monoclavir in a prominent position; Johnson&Johnson has brought the world's first show of star drugs in the fields of mental diseases, solid tumors, blood tumors and other diseases; AstraZeneca has brought new achievements in the fields of rare diseases, autoimmunity, neutralizing antibodies of COVID-19, vaccines and infections.

Feng Bixia, vice president of GlaxoSmithKline (GSK), told reporters: "At present, we have entered the development stage of 'China Acceleration', the number of innovative products of the company has been increasing, and the speed of listing in China has also been greatly accelerated."

In terms of medical devices, Medtronic, Abbott, Johnson&Johnson, Siemens Medical, Bidi Medical, GE Medical, Philips Medical, etc. have all introduced "high precision and cutting-edge technology".

Chen Ying, global vice president of Abbott Core Diagnostics, said that Abbott will continue to open "the first show in Asia" and "the first show in China" of many cutting-edge life technologies in the world this year, such as Aveir? VR single chamber implantable leadless cardiac pacemaker, TactiFlex? Ablation Catheter,Sensor Enabled? Head end etching magnetoelectric positioning pressure monitoring ablation catheter, nutritional supplements that have been developed and produced in China.

The environment of China's market development and innovation is particularly attractive to giants. "In more than 130 years of Johnson&Johnson's history, innovation has always been our core competitiveness. China's efforts to promote high-quality development led by innovation have encouraged us and strengthened our confidence in long-term development here. Johnson&Johnson will continue to actively respond to the national call to continue to promote and deepen its innovation strategy from multiple dimensions." Song Weiqun said.

Giants come to China to seek "hematopoietic" opportunities

In addition to releasing new brands and products, the giants in the medical field have also found "incremental space" in the Chinese market: accelerating the implementation of innovative achievements, increasing investment in the Chinese market, expanding the localization layout of China, Huacheng Import and Export Data Observation Report.

GlaxoSmithKline has brought the herpes zoster vaccine, which has been approved for marketing in China, and turned the exhibits of the previous Expo into commodities. Feng Bixia said that since the exhibition of the previous World Expo, the herpes zoster vaccine products have achieved the bidding access in all provinces of China, and achieved rapid landing in 306 cities in China, covering more than 6500 vaccination sites.

By entering the Expo, the innovation achievements of transnational giants in the medical field have been accelerated to land in the Chinese market. Song Weiqun said that Johnson&Johnson has brought many internationally leading innovative products and medical solutions to all previous expositions. These exhibits have gained attention and recognition from all parties after being exhibited in the Expo, and they have also been rapidly landed in the Chinese market, better and faster to meet the health needs of the people.

Chen Ying also said that Abbott attaches great importance to this open communication platform and has fully enjoyed the fruitful results brought by the spillover effect of the Expo in the past two years. In the future, Abbott will continue to make cutting-edge life science and technology and high-quality medical resources more accessible through close communication and cooperation with industry partners, and deepen the market layout in China through continuous localization investment.

With the help of this window, the giants in the medical field have also found investment opportunities. Peng Yang, global vice president of Danaher and president of China Group, told reporters that Cytiva, a global pioneer in life sciences under the group, would announce to invest 60 million yuan in China to build a Chinese science and innovation center, and accelerate the innovation and high-quality development of the local biopharmaceutical industry by providing products, technologies, services and innovative solutions that run through the upstream and downstream. The total investment of Cytiva China Science and Technology Innovation Center after the capital increase will exceed 100 million yuan, Huacheng Import and Export Data Observation reported.

Peng Yang further said: "Over the past five years, the Expo has continued to play a window role in building a dual cycle between international and domestic markets, allowing us to more truly understand the huge market space and growth potential contained in the Chinese market."

China Innovation Promotes Global Innovation

Facing the Chinese market with huge development potential, giants have come to China to seize the innovation highland and incubate innovation achievements in the Chinese market.

For the giants, it is very important to set up R&D centers in the Chinese market. Song Weiqun said, "While Johnson and Johnson are constantly introducing the world's leading innovative products, they are also accelerating the cultivation of local innovative R&D capabilities. At present, our three major businesses of medical technology, pharmaceuticals and consumer health have R&D centers or R&D departments in China, with more than 700 scientists and R&D personnel. China is the only market outside the United States that Johnson and Johnson has end-to-end R&D capabilities in all three businesses."

Peng Yang also said that in 2023, Danaher will officially open its medical diagnosis platform R&D and manufacturing base in Suzhou, which has invested hundreds of millions of dollars, to meet the needs of local customers and patients more quickly with more competitive local innovative products and capabilities, and continue to contribute to the construction of a healthy China.

The giants not only innovate in the Chinese market, but also act as disseminators of Chinese innovation achievements. In addition to demonstrating innovative drugs, AstraZeneca also announced a series of investment plans in China at this year's Expo, such as investing about 450 million dollars to establish an inhalation aerosol factory in Qingdao High tech Zone; Invest 180 million yuan in Taizhou Global Supply Base to expand production capacity to supply Chinese and overseas markets. At the 3rd International Expo, AstraZeneca Zhongjin Medical Industry Fund, which was jointly established by AstraZeneca and CICC Capital, has successfully invested in more than 10 innovative enterprises in the Chinese market, Huacheng Import and Export Data Observation reported.

Wang Lei, AstraZeneca's global executive vice president, president of international business and China, said to the reporter of China Business Daily: "We attach great importance to China's innovation, its investment in independent innovation, its determination to lead the world in biomedical innovation and its achievements. We hope to make good use of the Chinese market to support innovation and development."